Pretargeted radioimmunotherapy (PRIT(TM)) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 1, 2000, Pages 15-29

  Weiden, Paul L ^a   Breitz, Hazel B ^a   Press, Oliver ^b   Appelbaum, Janet W ^c   Bryan, J Kyle ^c   Gaffigan, Sally ^c   Stone, Diane ^c   Axworthy, Don ^c   Fisher, Darrell ^d   Reno, John ^c  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Poniard Pharmaceuticals Inc   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

90Y; Non Hodgkin's lymphoma; Pretargeted radioimmunotherapy; PRIT; Radioimmunotherapy; RIT; Streptavidin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; STREPTAVIDIN; YTTRIUM 90;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; DOSIMETRY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; WHOLE BODY RADIATION;

EID: 18544410002     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.15     Document Type: Article

References (25)

1. Breitz HB., Weiden PL, Beaumier P, Axworthy DB, Seiler C, Su F-M, Graves S, Bryan K, Reno J. Pretargeted Radioimmunotherapy (PRIT) using Antibody-Streptavidin Conjugate and Radiobiotin: Phase I Study to Optimize Therapy Protocol. J Nucl Med 41:In press,2000.
2. Breitz H, Knox S, Weiden P, Goris M, Murtha A, Bryan J, Axworthy D, Seiler C, Su F-M, Beaumier P, Reno J. Pretargeted radioimmunotherapy with antibody-streptavidin and Y-90 DOTA-biotin (Avicidin): Result of a dose escalation study. J Nucl Med 1998;39:71P.
3. Jaffe ES. The role of immunophenotypic markers in the classification of non-Hodgkin's lymphomas. Semin Oncol 1990;17:11-19.
4. Theodore LJ, Axworthy DB. Cluster clearing agents. PCT Application Int'l. Publication No. WO97/46098, 1997.
5. Green NM. Avidin and Streptavidin. In: Wilchek M and Bayer E, eds. Methods of Enzymology. Avidin-Biotin Technology. 1990;184:51-67.
6. Axworthy DB, Reno JM. U.S. Patent 5,616,690, 1997.
7. 90Y Dual isotope scintillation counting method for patient samples from pretargeted cancer therapy phase I trial. J Nucl Med 1996;37:145P.
8. 90Y-DOTA-biotin with Pretargeted NR-LU-10/SA. Cancer Biotherapy and Radiopharm 1999;14(5):381-395.
9. Breitz HB, Weiden PL, Vanderheyden J-L, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB,Ratliff BA, Seiler CA, Foisie DC, et al. Clinical experience with Re-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992;33:1099-1109.
10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Group. Am J Clin Oncol 1982;5:649-655.
11. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R,Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17(4):1245-1253.
12. Press OW. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am 4 Suppl 1998;2:S19-26.
13. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246-3256.
14. DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF. 67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999;40:302-10.
15. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
16. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81.
17. Kaminski M, Zelenetz A, Press O, Selah M, Leonard J, Fehrenbacher L, Stagg R, Kross S, Tidmarsh G, Knox S, Vose J. Multicenter phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 1998;92 Suppl 1:316a. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
18. Kaminski M, Zelenetz A, Press O, Selah M, Leonard J, Fehrenbacher L, Stagg R, Kross S, Tidmarsh G, Knox S, Vose J. Multicenter phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 1998;92 Suppl 1:316a. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
19. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336-40.
20. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70.
21. 90Yttrium radioimmunotherapy in non-Hodgkin's lymphoma (NHL). J Nucl Med 1999;40:64P.
22. Fritzberg AR. Antibody pretargeted radiotherapy: a new approach and a second chance. J Nucl Med 1998;39:20N-22N.
23. Knox SJ, Goris ML, Weiner LM, Tempero M, Weiden PL, Gentner L, Breitz H, Axworthy D, Seiler C, Bryan K, Fisher DR, Horak ID. Phase II trial of Yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res, in press.
24. Weiden PL, Small EJ, Hudes GR, Knox SJ, Hawkins R, Breitz H, Adams G, French J, Gaffigan S, Bryan K, Horak ID, Gentner L. A phase II trial of pretargeted radioimmunotherapy (PRIT™) in patients with metastatic hormone resistant prostate cancer (HRPC). J Clin Oncol 1999;18:313a(1999).
25. Weiden PL, Small EJ, Hudes GR, Knox SJ, Hawkins R, Breitz H, Adams G, French J, Gaffigan S, Bryan K, Horak ID, Gentner L. A phase II trial of pretargeted radioimmunotherapy (PRIT™) in patients with metastatic hormone resistant prostate cancer (HRPC). J Clin Oncol 1999;18:313a.